- Home
- HCWB vs AQB Comparison
HCWB vs AQB Comparison
Compare HCWB & AQB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCWB | AQB |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HCWB | AQB |
|---|---|---|
| Price | $0.35 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 21.9M | 16.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.66 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,099,750.00 | $2,472,659.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $0.60 |
| 52 Week High | $17.80 | $2.95 |
Technical Indicators
Market Signals| Indicator | HCWB | AQB |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 59.83 |
| Support Level | $0.25 | $0.86 |
| Resistance Level | $0.78 | $1.00 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 55.61 | 82.56 |
Price Performance
Historical ComparisonAbout HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.